Abnormal echocardiography 7 days after stem cell transplantation may be an early indicator of thrombotic microangiopathy

Biol Blood Marrow Transplant. 2015 Jan;21(1):113-8. doi: 10.1016/j.bbmt.2014.09.028. Epub 2014 Oct 6.

Abstract

Cardiac complications after hematopoietic stem cell transplantation (HSCT) can lead to significant morbidity and mortality. Cardiac evaluation during the first 100 days after HSCT is usually performed only if clinically indicated, and no studies have examined whether routine screening is beneficial in this patient population at high risk for tissue injury. We conducted a single-center prospective clinical study to screen for cardiac complications in pediatric and young adult patients. One hundred consecutive HSCT patients underwent scheduled echocardiographic screening on day +7 after transplantation, independent of their clinical condition. At least 1 abnormality was identified in 30% of cases. Seventeen children had a pericardial effusion, 13 elevated right ventricular pressure, and 3 reduced left ventricular function. Survival was reduced in children with any echocardiographic abnormality at day 7 (67% versus 80% in those with and without, respectively, abnormality, P = .073). Moreover, raised right ventricular pressure at day +7 was significantly associated with transplant-associated thrombotic microangiopathy (TA-TMA; P = .004) and may indicate early vascular injury in the lungs. These data suggest that echocardiography 7 days after HSCT can detect early cardiac complications of HSCT and may identify early vascular injury associated with TA-TMA.

Keywords: Echocardiography; Hematopoietic stem cell transplantation; Left ventricle depression; Pericardial effusion; Pulmonary hypertension; Thrombotic microangiopathy.

Publication types

  • Clinical Trial

MeSH terms

  • Acute Disease
  • Antineoplastic Agents / therapeutic use
  • Child
  • Child, Preschool
  • Chronic Disease
  • Female
  • Graft vs Host Disease / immunology
  • Graft vs Host Disease / mortality
  • Graft vs Host Disease / pathology
  • Hematologic Neoplasms / diagnostic imaging
  • Hematologic Neoplasms / mortality
  • Hematologic Neoplasms / pathology*
  • Hematologic Neoplasms / therapy
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Humans
  • Lung / blood supply
  • Lung / pathology
  • Male
  • Pericardial Effusion / etiology
  • Pericardial Effusion / mortality
  • Pericardial Effusion / pathology*
  • Pericardial Effusion / therapy
  • Prospective Studies
  • Survival Analysis
  • Thrombotic Microangiopathies / etiology
  • Thrombotic Microangiopathies / mortality
  • Thrombotic Microangiopathies / pathology*
  • Thrombotic Microangiopathies / therapy
  • Tissue Donors
  • Transplantation Conditioning
  • Transplantation, Homologous
  • Treatment Outcome
  • Ultrasonography
  • Ventricular Dysfunction, Left / etiology
  • Ventricular Dysfunction, Left / mortality
  • Ventricular Dysfunction, Left / pathology*
  • Ventricular Dysfunction, Left / therapy
  • Ventricular Dysfunction, Right / etiology
  • Ventricular Dysfunction, Right / mortality
  • Ventricular Dysfunction, Right / pathology*
  • Ventricular Dysfunction, Right / therapy

Substances

  • Antineoplastic Agents